Taiwan’s pharmaceutical industry was based primarily on generic drugs, and over the years prior to year 2000, core capabilities for the development and manufacture of generic drugs had been largely established. However, it has become increasingly difficult to foster the further growth and increase the profitability of the industry, due to the factors including: drug price-cutting policies by the National Health Insurance Bureau, export restrictions by foreign countries,....